CHANGE M MAY 30, Page 1 Page 1. CHAPTER 8 Section 9.1, pages 1 and 2 Section 9.1, pages 1 and 2

Similar documents
Chapter 8 Section 9.1

Chapter 8 Section 9.1

CHAPTER 8 Section 9.1, pages 1 through 7 Section 9.1, pages 1 through 7. CHAPTER 10 Section 7.1, pages 1 and 2 Section 7.

PURPOSE OF THE POLICY STATEMENT OF THE POLICY PROCEDURES

TRICARE Operations Manual M, February 1, 2008 Claims Processing Procedures. Chapter 8 Section 2

Master Table of Contents, page 1 Master Table of Contents, page 1

PLAN F MEDICARE (PART A) HOSPITAL SERVICES PER BENEFIT PERIOD 2019

PLAN F MEDICARE (PART A) HOSPITAL SERVICES PER BENEFIT PERIOD

TRICARE Pharmacy Program

PLAN F or HIGH DEDUCTIBLE PLAN F MEDICARE (PART A) HOSPITAL SERVICES PER BENEFIT PERIOD

Uniform Formulary Solicitation, Price Quotes and Uniform Formulary Blanket Purchase Agreement

2019 Transition Policy

Chapter 24 Section 3

Harvard Pilgrim Health Care Pharmacy Services Policy & Criteria. Medicare Advantage Transition of Care

CHAPTER 12 SECTION 2.1 TRICARE OVERSEAS PROGRAM (TOP) - COSTS AND UNIFORM HMO BENEFITS

MCSC OPERATIONS MANUAL M, MAR 2001 PROVIDER NETWORKS CHAPTER 5 SECTION 1

I. PURPOSE. A. The primary objectives of Molina Healthcare s Transition Policy and Procedure are:

Blue Essentials, Blue Advantage HMO SM and Blue Premier SM Provider Manual - Pharmacy

NH School Health Care Coalition SCHOOLCARE 65+ January 1, Summary of Benefits

Harvard Pilgrim Health Care Pharmacy Services Policy & Criteria. Medicare Advantage Transition of Care

CHAPTER 12 SECTION 3.1 TRICARE - PHARMACY BENEFITS

YOUR TRUST PLAN BENEFITS

Martin s Point Generations Advantage Policy and Procedure Form

Part TRICARE Retiree Dental Program (TRDP)

Excellus BlueCross BlueShield Participating Provider Manual. 5.0 Pharmacy Management

2019 Transition Policy and Procedure

TRICARE Pharmacy Voluntary Agreement for Retail Refunds (Additional Refund) for Uniform Formulary Placement (UF-VARR)

Impact of the AMP Final Rule on Class of Trade & Contracting

Medicare Transition POLICY AND PROCEDURES

YOUR TRUST PLAN BENEFITS

**** CMS Regulation-Action Required****

Community Care, Inc. Medicare Part-D Enrollee Transition Plans H5212 PACE and H2034 HMO-SNP 2018

PEP-Portland Clinical Practices Policy Number: CP Policy Owner: Health Plan Operations Manager New Revised Reviewed

Glossary of Terms (Terms are listed in Alphabetical Order)

Prescription Drug Coverage

Overview of the BCBSRI Prescription Management Program

The Health Plan has processes in place that explain how members, pharmacists, and physicians:

2018 Transition Fill Policy & Procedure. Policy Title: Issue Day: Effective Dates: 01/01/2018

2012 Medicare Part D Transition Process for contracts H3864 & H4754:

Y0076_ALL Trans Pol

TRANSITION POLICY. Members Health Insurance Company

Values Accountability Integrity Service Excellence Innovation Collaboration

NCPA Summary of CMS Medicaid Covered Outpatient Drugs AMP Final Rule Prepared January NCPA Advocacy at Work

Pharmaceutical Management Commercial Plans

PLEASE CHECK ALL BOXES THAT APPLY AND COMPLETE THE APPROPRIATE SECTION(S) OF THE FORM. Patient name: Date of birth: Sex: M F

Aging Into Medicare and TRICARE For Life

How are allowable charge determinations to be made in the determination of reimbursement for 1992 and forward?

White Paper: Formulary Development at Express Scripts

Appendix. Year Total drug spending reaching catastrophic coverage, $

All Medicare Advantage Products with Part D Benefits

The Merck Access Program ENROLLMENT FORM

BlueScript Pharmacy Program Endorsement

Highlights of the Group Retiree Medical Plan for Schools Insurance Group Retirees

OFFICE OF THE ASSISTANT SECRETARY OF DEFENSE HEALTH AFFAIRS EASTCENTRETECH PARKWAY AURORA, CO

Re: CMS 2238 FC (Final Rule: Medicaid Program; Prescription Drugs)

TRICARE Reimbursement Manual M, February 1, 2008 Double Coverage. Chapter 4 Section 4

POLICY AND PROCEDURE DEPARTMENT: Pharmacy Operations

Medicare Part D Transition Policy CY 2018 HCSC Medicare Part D

Managing Specialty Pharmaceuticals: Balancing Access and Affordability

CRS Report for Congress Received through the CRS Web

BlueScript Pharmacy Program Endorsement

MEDICARE PART D POLICY FORMULARY: TRANSITION PROCESS Policy Number: 6-C

MOAA PUBLICATIONS: YOUR RESOURCE FOR EVERY STAGE OF LIFE. Aging Into Medicare. and TRICARE For Life

Medicare Advantage Part D Pharmacy Policy

Chapter 7 Section 4. Residential Treatment Center (RTC) Reimbursement

Master Table of Contents, pages 1 and 2 Master Table of Contents, pages 1 and 2. CHAPTER 8 Section 6, pages 5 through 7 Section 6, pages 5 through 7

Putting the Pieces Together, a Review of the Benefits Investigation Process. Thomas Cohn, Asembia

PROPOSED AMENDMENTS TO HOUSE BILL 4156

CHAPTER 58-29E PHARMACY BENEFITS MANAGEMENT

Individual Business Prescription Drug Utilization Management Changes Frequently Asked Questions

2018 Medicare Part D Transition Policy

Committee/Subcommittee hearing bill: Health & Human Services Committee Representative Santiago offered the following:

Pharmaceutical Management Community Plans 2018

CHAPTER 3 Section 4, pages 1 and 2 Section 4, pages 1 and 2. CHAPTER 20 Section 2, pages 3 through 8 Section 2, pages 3 through 8

Prescription Drug Rider

Chapter 1 Section 38. Reimbursement of State Vaccine Programs (SVPs)

DEPARTMENT OF VETERANS AFFAIRS Civilian Health and Medical Program of the Department of Veterans Affairs

Chapter 13 Section 2. Controls, Education, and Conflicts of Interest

Chapter 25 Section 1

Highlights of the Group Medicare Prescription Drug Plan. Administrative Services from Group Administrative Concepts

Medicaid Program; Covered Outpatient Drugs; Proposed Rule (CMS-2345-P) NHIA Summary

Chapter 25 Section 1

Arkansas State University System Prescription Drug Program

Part II: Medicare Part C and Part D

POLICY STATEMENT: PROCEDURE:

Summary of Benefit Plan Changes and Clarifications

MEMORANDUM FOR PHARMACY AND THERAPEUTICS COMMITTEE. SUBJECT: Implementation of Final Rule on Federal Ceiling Prices

Chapter 26 Section 1

CHAPTER Senate Bill No. 2508

2015 PacificSource Medicare Part D Transition Process for contracts H3864 & H4754:

Prescription Drug Brochure


A. Update to TC-001 (04/13), GENERAL TERMS AND CONDITIONS OF PURCHASE

Managed Care Pharmacy Commercial Perspective

Exploring the Interaction between Medicare Part B and Medicare Part D

3. Prescription Drug Plan Options

Florida Medicaid. Prescribed Drugs Services Coverage Policy. Agency for Health Care Administration. Draft Rule

79th OREGON LEGISLATIVE ASSEMBLY Regular Session. House Bill Corrected Sponsor

Value Three-Tier EFFECTIVE DATE: 01/01/2016 FORM #1779_03

Chapter 17 Section 2

Transcription:

CHANGE 24 6010.60-M MAY 30, 2018 REMOVE PAGE(S) INSERT PAGE(S) FOREWORD FOREWORD Page 1 Page 1 CHAPTER 8 Section 9.1, pages 1 and 2 Section 9.1, pages 1 and 2 2

HPOB April 1, 2015 Foreword Revision: C-24, May 30, 2018 The TRICARE Policy Manual (TPM) 6010.60-M, in conjunction with the TRICARE Reimbursement Manual (TRM), 6010.61-M, contains operational policy necessary to efficiently implement the Code of Federal Regulations at 32 CFR 199. This manual augments the 32 CFR 199 and must be used in conjunction for complete policy information, providing guidance, policy interpretation and decisions implementing TRICARE, including those policies and procedures applicable to the TRICARE Health Plan. The Department of Defense (DoD) has a License Agreement with the American Medical Association (AMA) regarding the use of the Physician s Current Procedural Terminology (CPT), a coding work of medical nomenclature developed by the AMA. In accordance with the terms of that Agreement, the DoD has agreed to: 1. Include a Copyright notice in every section that references CPT codes; 2. Specifically identify procedure codes as CPT procedure codes; 3. Use only short descriptions with CPT codes and delete all long descriptions; and 4. Italicize short descriptions wherever they are used. The TRICARE Manuals provide instructions, guidance and responsibilities in addition to the requirements set forth in the incorporated federal statutes and the regulations and may not be interpreted in contradiction thereto. John L. Arendale, Branch Chief Health Plan Operations Branch (HPOB) Defense Health Agency (DHA) Definitions are available in the Apr 2015 TRICARE Operations Manual (TOM), Appendix A. Acronyms and abbreviations are available at http://manuals.tricare.osd.mil/pages/v3/ DownloadManualFile.aspx?Filename=Acronyms.pdf. 1 C-24, May 30, 2018

ATTENTION Links from the documents contained within this manual (and placed on the TRICARE Manuals web site) may include links providing direct access to other Internet resources, including web sites. Because of the dynamic nature of the Internet, Defense Health Agency (DHA) cannot be responsible for the accuracy of or content of information contained in the links to other web sites.

TRICARE Policy Manual 6010.60-M, April 1, 2015 Other Services Chapter 8 Section 9.1 Pharmacy Benefits Program Issue Date: August 2002 Authority: 32 CFR 199.2(b), 32 CFR 199.4(b)(2)(vi), (b)(3)(iii), (b)(5)(v), (d)(3)(vi), (e)(11)(i), 32 CFR 199.5(d)(12); 32 CFR 199.17, and 10 USC 1074g Revision: C-24, May 30, 2018 1.0 DESCRIPTION 1.1 General The TRICARE Pharmacy (TPharm) benefit includes retail and mail order prescription services, medications provided by physicians and other appropriate clinicians, and pharmaceutical agents provided in support of home health care. TRICARE uses a number of contractors to administer the benefit. 1.2 Retail Prescription Service Retail pharmacy services, network and non-network, will be provided under a TPharm contract and will be subject to the Uniform Formulary. The TRICARE formulary is found at http:// www.health.mil/selectdruglist. The retail pharmacy contractor is responsible for administering claims related to pharmaceuticals dispensed by an authorized provider with a National Council of Prescription Drug Programs (NCPDP) or other nationally recognized pharmacy designation. 1.3 Mail Order Prescription Service Mail order prescription services are provided under a TPharm contract and will be subject to the Uniform Formulary. The TRICARE formulary is found at http://www.health.mil/selectdruglist. 1.4 Medical Claims That Include Pharmaceutical Agents Pharmaceutical agents provided by physicians and other appropriate clinicians, and pharmaceutical agents provided in support of home health care are processed by the contractor(s). Claims for pharmaceutical agents (e.g., injectables) not appropriate for self-administration are the responsibility of the contractor. 1.5 Infusion Drug Therapy Delivered In The Home When injectable and infusion drug therapy are medically necessary, and delivery and administration in the home is appropriate the contractor shall provide prior authorization of injectable or infused drugs to a TRICARE authorized pharmacy in order for the pharmaceutical agent to be fulfilled under the pharmacy benefit pursuant to Section 20.1, Infusion Drug Therapy Delivered in the Home. 1 C-24, May 30, 2018

1.6 Overseas Claims TRICARE Policy Manual 6010.60-M, April 1, 2015 Chapter 8, Section 9.1 Pharmacy Benefits Program The TRICARE overseas claims processor (see the TRICARE Operations Manual (TOM), Chapter 24, Section 9) processes pharmaceutical claims from most overseas locations. As of June 1, 2004, the TPharm contractor processes network and non-network retail pharmaceutical claims in Puerto Rico, the U.S. Virgin Islands, Northern Mariana Islands, and Guam. 2.0 POLICY 2.1 Formulary Formulary management will be the responsibility of the Government as defined by 32 CFR 199.21, Pharmacy Benefits Program. This regulation establishes procedures for the inclusion of pharmaceutical agents on a Uniform Formulary based upon relative clinical effectiveness and cost effectiveness; establishes cost-sharing requirements, including a tiered copayment structure, for generic, formulary and non-formulary pharmaceutical agents; establishes procedures to assure the availability of pharmaceutical agents not included on the Uniform Formulary to eligible beneficiaries at the non-formulary cost-share tier; establishes procedures to provide, when clinically necessary, pharmaceutical agents not included on the Uniform Formulary under the same terms and conditions as an agent on the Uniform Formulary; establishes procedures to assure the availability of clinically appropriate non-formulary pharmaceutical agents to members of the uniformed services; establishes procedures for prior authorization when required; and establishes a Department of Defense Pharmacy and Therapeutics Committee (DoD P&T Committee) and a Uniform Formulary Beneficiary Advisory Panel. All formulary decisions, to include prior authorization requirements, designation of nonformulary agents, quantity limits, and other medication use policies will be communicated to all contractors who have responsibility for administering the pharmacy benefit. 2.2 General Prescription Coverage 2.2.1 The Pharmacy Benefits Program generally requires mandatory substitution of generic drugs in accordance with 32 CFR 199.21(i)(2). If state law prohibits generic substitution on drugs, the contractor, at the direction of the Government, shall be able to process the brand product. 2.2.2 Eligible beneficiaries shall pay a copayment for drug claims that are cost-shared under the Pharmacy Benefit Program in accordance with the TRICARE Reimbursement Manual (TRM), Chapter 2, Addendum B. Section 702 of National Defense Authorization Act (NDAA) 2018 states the cost-sharing amounts for a dependent of a member of uniformed services who dies while on active duty, a member retired under Chapter 61, or a dependent of a member retired under such chapter shall be equal to the cost-sharing amount, if any, for 2017. 2.2.3 TRICARE is the secondary payor on claims where Other Health Insurance (OHI) coverage exists. OHI claims are reimbursed in accordance with TRM, Chapter 4, Section 3. Reimbursement will be the lesser of the TRICARE allowed amount or the remaining amount after OHI payment. 2.2.4 Labeled Indications. Pharmaceutical agents may be cost-shared when: The pharmaceutical agent is approved for marketing by the U.S. Food and Drug Administration (FDA); 2